Introduction
The risk of stroke in atrial fibrillation patients is high, especially among patients with a history of ischemic stroke or transient ischemic attack 1 . Stroke prevention in atrial fibrillation has conventionally involved anticoagulant therapy with vitamin K antagonists (VKA) such as warfarin 2 , but a narrow therapeutic range makes optimal treatment challenging. Dabigatran etexilate is a direct thrombin inhibitor whose rapid and predictable response can mitigate the complexity of conventional anticoagulant therapy. Trials and subsequent observational studies in mixed patient populations have shown dabigatran to provide comparable or slightly improved protection against stroke and systemic embolism, without compromising bleeding safety [3] [4] [5] .
Trial-based findings within the clinically important subgroup of patients with prior stroke have been consistent with the overall efficacy and safety profile results for dabigatran. A predefined sub-study of the RE-LY study (Randomized Evaluation of Long Term Anticoagulant Therapy) found similar or slightly lower rates of stroke and systemic embolism among patients with a prior stroke/transient ischemic attack (2.78% for warfarin, 2.32% for dabigatran 110 mg bid; 2.07% for dabigatran 150 mg bid) 6 . In an indirect comparison of three new oral anticoagulants (apixaban, rivaroxaban and dabigatran) using secondary prevention (previous stroke) trial subgroups 7 , we found that dabigatran had similar efficacy to warfarin for stroke/systemic embolism, ischemic stroke, and all-cause mortality. However, the extent to which these trial-based subgroup findings transfer to a practical clinical setting is currently unclear.
Analysis of observational data, while insufficient for providing unequivocal treatment recommendations, can provide valuable insight into medication effectiveness in a practical clinical setting. The present nationwide observational study shares design and data similarities with recent studies on myocardial infarction and bleeding risk with dabigatran and warfarin, but in the present study we focus only on patients with previous stroke 8, 9 . Specifically, we used prescription purchase data to assess the effectiveness of dabigatran relative to warfarin for secondary prevention in a realworld atrial fibrillation population with a history of stroke or transient ischemic attack. A substantial proportion of dabigatran initiators are patients who are switched from warfarin, so-called warfarin survivors 10 . In RE-LY, no differences were found in the prognosis between such warfarin survivors and new starters 11 . However, this finding may not transfer to a non-trial setting with more autonomous treatment management, particularly not in a high-risk patient group. Accordingly, we assessed the risk of stroke among patients with a history of stroke/ transient ischemic attack
separately within the stratum of 'switchers' from warfarin to dabigatran (compared to warfarin persisters); and within the stratum of 'new starters' on dabigatran (compared to new starters on warfarin).
Methods
We used the civil registration number assigned to all Danish residents to link three nationwide respectively VKA-experienced, if the time since the last warfarin purchase was ≥2 years, respectively <2, years. A relatively long period was used in order to also reflect naivety in relation to treatment routine.
From the purchase data, we defined a VKA-naïve stratum of all VKA-naïve subjects making a firsttime purchase of dabigatran. As controls in this stratum, we sampled the full population of VKA-
naïve subjects making a first-time warfarin purchase. The baseline date in the VKA-naïve stratum was set to the date of first purchase.
We next defined a VKA-experienced stratum of all VKA-experienced subjects purchasing dabigatran for the first time (switchers). Comparable controls were selected for each switcher by matched sampling among VKA-experienced warfarin controls. Specifically, 2 VKA-experienced warfarin users were matched to each switcher according to calendar month of purchase and duration of VKA-experience (up to 1 year; 1-5 years; more than 5 years). The baseline date in the VKAexperienced stratum was set to the date of (first) purchase in the calendar month of inclusion.
Endpoints and variable definitions
Participants were followed until July 31 2013 in the Danish National Patient Register (using the We estimated 3-month persistence probabilities 15 , defining time of non-persistence as the time of treatment switching or >30 days discontinuation (ascertained from previous package sizes and a standard daily dose).
A number of sensitivity/supplementary analyses were carried out. First, we repeated regression analyses after censoring individuals at the time of non-persistence in order to quantify the effect of continuous treatment (implicitly assuming censoring to be non-informative conditionally on baseline covariates). Second, to assess robustness to a more stringent endpoint definition (with presumably higher validity), regression analyses were also repeated when requiring endpoints to have been registered as the primary diagnosis in connection with hospitalization for at least one night. Lastly, we repeated a subset of the main analyses in the primary prevention group, i.e. the analogously defined two VKA-experience strata based on the subset of the warfarin/dabigatran purchase data that excluded subjects with a prior diagnosis of stroke/ transient ischemic attack.
Stata/MP version 12.1 was used for the statistical analysis. A two-sided P value <0.05 was considered as statistically significant.
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Results
Study population characteristics
A flow chart of the study population is shown in Figure 1 . In the VKA-naïve stratum, we included 1,439 patients with atrial fibrillation and a history of stroke/ transient ischemic attack making a first-time dabigatran purchase; alongside 1,825 patients making a first-time warfarin purchase (controls). In the VKA-experienced stratum, 959 dabigatran switchers where matched to 1,918
warfarin controls (selected among 11,159 unique subjects with a total of 76,553 purchases).
Baseline information is shown in Table 1 . Within each of the VKA-experience strata, D110 users were older, with a median age over 80 (compared to median ages below 76 and 70 for warfarin, respectively D150 users). Accordingly, D110 users also had a higher stroke and bleeding risk (according to CHADS 2 /CHA 2 DS 2 VASc and HAS-BLED scores). There were slightly more females than males in the D110 group (55% to 56%), but not in the D150 and the warfarin group (36% to 44% females). Comparing between VKA-experience strata, the age and gender distribution was similar for each of the three treatments. Patients in the VKA-experienced stratum generally had higher CHADS 2 /CHA 2 DS 2 VASc scores but a similar or slightly decreased HAS-BLED score.
There were substantially fewer clopidogrel users in the VKA-experienced stratum (3.0% to 5.8%) compared the VKA-naïve stratum (20.1% to 21.4%) in the VKA-naïve stratum; and also fewer aspirin users users (21.8% to 23.0%) than in the VKA-naïve stratum (34.8% to 43.0%).
Stroke and transient ischemic attacks
The average follow-up time was 12.6 months (standard deviation: 4.5 months). Plots of crude cumulative incidences for the composite endpoint of stroke/ transient ischemic attack (Figure 2) showed that, in the VKA-naïve stratum, D110 users had the lowest risk and D150 the highest risk, with the risk increasing more rapidly in the early follow-up period. The stroke risk in the VKAexperienced stratum was lower overall compared to the VKA-naïve stratum: within this stratum, warfarin users had the lowest and D110 users the highest risk.
In the VKA-naïve stratum ('new starters'), crude annual event rates of stroke/ transient ischemic attack ranged from 14.0% to 20.0% (Table 2 ). For the composite endpoint stroke/TIA, adjusted event rates showed a significant 36% reduction among D110 users in compared to warfarin (hazard M A N U S C R I P T Table 2) were generally low, ranging from 0.3% to 1.2%.
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Turning to the VKA-experienced stratum ('switchers'), crude annual event rates of stroke/ transient ischemic attack were overall substantially lower than in the VKA-naïve stratum, ranging from 4.8% to 10.8% (Table 2 ). For stroke/TIA, we saw a significant doubling of the event rate of for both D110 and D150 compared to warfarin (D110 HR 1.99, 95% CI: 1.42-2.78; D150 HR 2.34, 95% CI:
1.60-3.41). When considering stroke and transient ischemic attack separately, comparably sized increases in adjusted rates for dabigatran relative to warfarin. There were again few fatal strokes/ transient ischemic attack (not shown in Table 2 ), with crude annual rates ranging from 0.2% for D150 (0.3% for warfarin), to 2.3% for D110.
Treatment persistence and supplementary analyses
Persistence probabilities at 3 months were 87% (warfarin), 79% (D110), and 82% (D150) in the VKA-naïve stratum; 91% (warfarin), 81% (D110), and 84% (D150) in the VKA-experienced stratum.
The persistence-adjusted Cox regression gave similar results as the main analysis (Supplementary 
respectively). Of note, the primary prevention group was substantially younger than the secondary prevention group; and with lower stroke and bleeding risks, according to the CHADS 2 /CHA 2 DS 2 VASc and HAS-BLED scores, respectively (Supplementary Table 6 ).
Discussion
In this large register-based observational study of secondary stroke prevention among atrial fibrillation patients, we found similar effectiveness of dabigatran relative to warfarin for secondary prevention of stroke/ transient ischemic attack among 'new starters' on anticoagulant therapy. In contrast, we found a doubling of the stroke/ transient ischemic attack rate among 'switchers' to both dabigatran doses compared to persisters on warfarin. The overall stroke risk was generally higher in 'new starters' on anticoagulant therapy regardless of therapy. A supplementary analysis in the primary stroke prevention group indicated no differences in stroke risk relative to warfarin for both 'new starters' and 'switchers' on dabigatran, except for switchers to D110 who were at an increased risk of stroke/TIA.
Altogether, our study suggests that caution and vigilance is needed when switching prior VKAexperienced atrial fibrillation patients to dabigatran, especially for patients who are able to consistently maintain a high average time in therapeutic range. The extent to which the increased risk with dabigatran can be attributed to the intervention of switching is, however, not clear, particularly in the light of the findings from randomized trials. A predefined sub-study of RE-LY among participants with prior stroke/ transient ischemic attack found no significant difference between both dabigatran doses and warfarin in relation to the risk of stroke or systemic embolism 16 .
Of note, there were several key differences from the present study: for example, prior VKA experience was not explicitly accounted for, participants were much younger, and recurrent stroke rates were lower. However, in the phase III trial on rivaroxaban versus warfarin 17, 18 , a marked increase in cardiovascular events were seen during the transition to open label therapy for patients switching therapy at the end of the trial. Meta-analyses and indirect comparisons have thus far confirmed the non-inferiority findings from the RE-LY subgroup studies 7, 19 .Divergent findings in an observational study necessitate caution since design limitations can easily induce spurious results. Bias due to residual or unmeasured confounding by indication is a serious concern: an apparent treatment effect may simply reflect unaccounted indications for which the treatment was M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
administered. In the present study, clinicians may have been more likely to switch patients with difficulties maintaining a high time in therapeutic range. Since INR measurements are not available from the registries, we were unable to investigate this. While confounding bias alone is a viable explanation for our findings, it does raise new questions about the sources of such confounding.
Indeed, in our analyses, we adjusted for variables that a priori would be expected to be strong
confounders, yet we observed only a modest change in the crude point estimates. If confounding bias were to completely explain our findings, we speculate that there would either have to be many unmeasured confounders with a moderate effect or a few very strong unmeasured confounders. As a crude, quantitative assessment, a binary unmeasured confounder with a prevalence of 80% among switchers and 20% among warfarin persisters would only completely explain a Cox model HR of 1.7 if the confounder triples the rate of stroke/ transient ischemic attack 20 .
A combination of confounding bias and (causal) effects due to treatment switching may also explain our divergent findings. Patients may be less protected in the early period following a switch from warfarin, for example because of 'latent' strokes previously prevented by warfarin and appearing after warfarin discontinuation -or simply because the patient is less familiar with the new treatment.
Indeed, plots of crude incidences lend some support to the observation that the early period after switching is a higher risk period. Lastly, irrespective of whether or not our findings are partly attributable to drug-related causal effects, they still convey the important message that real world prior stroke/ transient ischemic attack 'switchers' from warfarin to dabigatran represent a high risk group. Our study may offer a valuable insight for a future randomized trial of outcomes after treatment switching.
We conclude by commenting on the overall stroke risk differences between VKA-naïve and VKAexperienced users which were clearly visible from Figure 2 . These are likely to be attributable to the 'healthy user' selection inherent in the definition of the VKA-experienced stratum: to be included in the VKA-experienced stratum, one has to survive the time from treatment initiation to study inclusion with at most one stroke. The differences apparent in Figure 2 emphasize the appropriateness of treating the VKA-naïve and VKA-experienced stratum separately.
Limitations of the present observational study in terms of confounding bias have already been discussed, with the lack of INR measurements being a particular concern. Also, the accuracy of the proposed "intention-to-treat approach" relies on patients actually taking their drugs, as is the case for all comparative effectiveness studies. While the validity of an ischemic stroke diagnosis is high M A N U S C R I P T
in the Danish Registry of Patients 21 , misclassification is also a relevant limitation (reassuringly, a more stringent definition of endpoints lead to results consistent with our main analysis). Lastly, one should be aware of the limitations of a comparative effectiveness study of a newly-marketed drug such as dabigatran; these can include channeling of selected patient groups towards the new drug, as well as time-varying user population characteristics 22 . Strengths of the study include the use of large 'real world' atrial fibrillation population, the long follow-up period, and the completeness of the registries.
Conclusion
In this nationwide cohort study, we found that for patients with a history of stroke/ transient ischemic attack who are VKA-naïve, both dabigatran doses provided similar protection to warfarin against recurrent stroke/TIA. Among VKA-experienced patients, the risk of recurrent stroke/ transient ischemic attack was significantly increased compared to continued warfarin usage.
Although clinical implications from observational data must be drawn carefully, our findings stress the importance of caution and vigilance when switching prior VKA-experienced atrial fibrillation patients to dabigatran, especially for patients with prior good quality anticoagulation as reflected by a high time in therapeutic range.
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which reflect the risk of bleeding in atrial fibrillation patients undergoing anticoagulant therapy (see Supplementary   Table 2) . Abbreviation: SD = Between-subjects standard deviation, NSAID = Non-steroidal anti-inflammatory drugs M A N U S C R I P T We identified subjects with hypertension from combination treatment with at least two of the following classes of antihypertensive drugs:
I. Alpha adrenergic blockers (C02A, C02B, C02C) II. Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52) III. Vasodilators (C02DB, C02DD, C02DG, C04, C05) IV. Beta blockers (C07) V. Calcium channel blockers (C07F, C08, C09BB, C09DB) VI. Renin-angiotensin system inhibitors (C09). Abbreviations: CI = confidence interval M A N U S C R I P T
